• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Three ultrasonographic findings portend increased risk of malignancy in thyroid nodules

bys25qthea
August 28, 2013
in Chronic Disease, Endocrinology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Three ultrasound characteristics of thyroid nodules were indicative of increased risk of cancer including: microcalcifications, size greater than 2 cm and entirely solid composition. 

2. Limiting biopsy to patients with only microcalcifications or greater than two high-risk ultrasound features would eliminate up to 90% of all biopsies with a cancer risk of only 0.5% in unbiopsied nodules.  

Evidence Rating Level: 3 (Average) 

Study Rundown: There is a high incidence of thyroid nodules in the general population, but only a small percentage of these are malignant.  Furthermore, many thyroid neoplasms may never become clinically significant.  This study identifies 3 high risk ultrasonographic features of malignant thyroid nodules by comparing thyroid ultrasounds of known malignant nodules with those of non-cancerous nodules.  By using the California Cancer Registry to identify cases of thyroid cancer within the study population of all people who underwent thyroid ultrasound at UCSF during the study period, this study avoided the ascertainment bias of prior studies, which looked only at nodules which underwent biopsy.

The study found that only 3 ultrasonographic findings conveyed an increased risk of malignancy including: microcalcifications, size >2cm and entirely solid composition.  Other characteristics did not signify an increased risk of cancer.  Based on their model, they suggest that reasonable criteria for biopsy would be the presence of microcalcifications or 2 or more of the criteria, which would yield a false negative rate of only 0.5% and would substantially reduce the number of biopsies performed.  This study is limited by the fact that it is based on data from only one institution, and there was a minimum of only 2 years of follow-up, so clinically significant cancers could have developed after the study period, and would not be captured by this analysis.

RELATED REPORTS

Postoperative radioiodine ablation does not reduce cancer recurrence following thyroidectomy

#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

Fine needle biopsy remains a reliable test for thyroid cancer diagnosis

Click to read the study in JAMA Internal Medicine

Relevant Reading: Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer

In-Depth [retrospective case-control study]: This study included a total of 11,618 examinations performed on 8,806 patients, of whom 105 were subsequently diagnosed with cancer of the thyroid. It was found that the presence of microcalcifications in a thyroid nodule conveyed the highest risk of malignancy and were present in 38.2 % of cancerous nodules as compared to 5.4% of benign nodules (OR, 8.1; 95% CI, 3.8-17.3; P<.001).  Size >2cm was also associated with an increased risk of malignancy (OR, 3.6; 95% CI, 1.7-7.6; P=.001), as was an entirely solid composition (OR, 4.0; 95% CI, 1.7-9.2; P=.001).  They found that the presence of any one of these characteristics was 88% sensitive for malignancy, but was non-specific and carried a risk of cancer of only 1.8% (95% CI, 0.015-0.022).  The presence of microcalcifications alone conveyed an 8.2% (95% CI, 0.059-0.110) increased risk of cancer, while the presence of any 2 features had a 6.2% (95% CI, 0.047-0.080) increased risk.  The number needed to biopsy in order to diagnose cancer was 12 (95% CI, 9-17) for microcalcifications, 16 (95% CI, 13-21) for any 2 features, as compared to 56 (95% CI, 45-67) for any single feature alone.

By Evan Shalen and Brittany Hasty

More from this author: Healthy diet delays development, progression of chronic kidney disease in diabetics

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: thyroid cancer
Previous Post

Sofosbuvir, ribavirin achieve high rates of Hepatitis C virus remission in toughest cases

Next Post

The Val-HeFT trial: Valsartan reduces morbidity in chronic heart failure [Classics Series]

RelatedReports

Selpercatinib may provide an effective response against RET-mutated thyroid cancer
Chronic Disease

Postoperative radioiodine ablation does not reduce cancer recurrence following thyroidectomy

July 31, 2025
#VisualAbstract: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
StudyGraphics

#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

November 24, 2023
Patient Basics: Thyroid Cancer
Chronic Disease

Fine needle biopsy remains a reliable test for thyroid cancer diagnosis

October 19, 2022
Oncology

More permissive parameters for active surveillance eligibility is potentially possible in slow-growing thyroid cancers

September 26, 2022
Next Post

The Val-HeFT trial: Valsartan reduces morbidity in chronic heart failure [Classics Series]

Angiotensin-receptor blockers in diabetic nephropathy [Classics Series]

One-year of Herceptin preferable to two-year regimen

Terminology used to describe ductal carcinoma in situ impacts patient preferences

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind September 1, 2025
  • Significant body weight reduction with cagrilintide-semaglutide therapy
  • Machine learning models diagnose celiac disease at similar performance levels to pathologists
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.